Canaccord Genuity Maintains Buy on Globus Medical, Raises Price Target to $60

Canaccord Genuity maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $57 to $60.

Benzinga · 11/07/2019 17:18

Canaccord Genuity maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $57 to $60.